(Q54037239)

24 May 2018

title

A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. (English)

1 reference

24 May 2018

1 reference

M Giusti

1

1 reference

24 May 2018

E Porcella

2

1 reference

24 May 2018

A Carraro

3

1 reference

24 May 2018

M Cuttica

4

1 reference

24 May 2018

S Valenti

5

1 reference

24 May 2018

G Giordano

6

1 reference

24 May 2018

publication date

1 January 1994

1 reference

24 May 2018

Journal of Endocrinological Investigation

published in

1 reference

24 May 2018

volume

17

1 reference

24 May 2018

issue

1

1 reference

24 May 2018

page(s)

51-57

1 reference

24 May 2018

Management of prolactinomas

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

CV 205-502 treatment of hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Drugs five years later. Bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03344963

Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502

21 January 2018

1 reference

12 December 2020

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

1 reference

12 December 2020

Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine

1 reference

12 December 2020

Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas

1 reference

12 December 2020

Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502

1 reference

12 December 2020

Parenteral bromocriptine in the treatment of hormonally active pituitary tumours

1 reference

12 December 2020

Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia

1 reference

12 December 2020

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: A double-blind study

1 reference

12 December 2020

Hyperprolactinemia. Evaluation and management

1 reference

12 December 2020

A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients

1 reference

12 December 2020

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03344963

1 reference

24 May 2018

release_ieb545tzczh5zeb6rs3pik7hwi

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ieb545tzczh5zeb6rs3pik7hwi

24 November 2022

mapped directly with Wikidata item

1 reference

24 May 2018